Chimerix’s (CMRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $11.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Wedbush reaffirmed an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Thursday, November 7th.

Chimerix Stock Performance

Shares of CMRX opened at $0.90 on Monday. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30. The company has a market capitalization of $80.83 million, a PE ratio of -0.96 and a beta of 1.13. The stock has a fifty day moving average of $0.90 and a two-hundred day moving average of $0.91.

Chimerix (NASDAQ:CMRX) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter last year, the company posted ($0.21) earnings per share. As a group, equities research analysts forecast that Chimerix will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Chimerix

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares during the period. Marshall Wace LLP acquired a new position in Chimerix during the second quarter valued at approximately $137,000. Acadian Asset Management LLC grew its stake in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after buying an additional 291,981 shares during the period. Finally, Koshinski Asset Management Inc. acquired a new stake in shares of Chimerix in the first quarter worth $42,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.